A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Guardant Health, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 19,294 shares of GH stock, worth $629,949. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,294
Holding current value
$629,949
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$22.3 - $36.29 $430,256 - $700,179
19,294 New
19,294 $442,000
Q1 2022

May 11, 2022

SELL
$48.25 - $100.49 $201,685 - $420,048
-4,180 Closed
0 $0
Q4 2021

Feb 08, 2022

SELL
$88.71 - $120.43 $95,984 - $130,305
-1,082 Reduced 20.56%
4,180 $418,000
Q3 2021

Nov 02, 2021

BUY
$98.77 - $132.17 $4,740 - $6,344
48 Added 0.92%
5,262 $658,000
Q2 2021

Aug 11, 2021

SELL
$109.77 - $165.68 $46,103 - $69,585
-420 Reduced 7.45%
5,214 $648,000
Q1 2021

May 14, 2021

BUY
$127.04 - $179.1 $103,156 - $145,429
812 Added 16.84%
5,634 $860,000
Q4 2020

Feb 12, 2021

BUY
$99.96 - $135.93 $162,834 - $221,429
1,629 Added 51.02%
4,822 $621,000
Q3 2020

Nov 04, 2020

SELL
$80.32 - $111.8 $44,657 - $62,160
-556 Reduced 14.83%
3,193 $357,000
Q2 2020

Jul 17, 2020

SELL
$60.49 - $97.5 $22,199 - $35,782
-367 Reduced 8.92%
3,749 $304,000
Q1 2020

Apr 21, 2020

SELL
$59.04 - $88.81 $8,796 - $13,232
-149 Reduced 3.49%
4,116 $286,000
Q4 2019

Feb 12, 2020

SELL
$59.49 - $82.78 $3,688 - $5,132
-62 Reduced 1.43%
4,265 $333,000
Q3 2019

Nov 07, 2019

SELL
$62.59 - $110.3 $148,213 - $261,190
-2,368 Reduced 35.37%
4,327 $276,000
Q2 2019

Aug 06, 2019

BUY
$63.94 - $91.11 $188,239 - $268,227
2,944 Added 78.49%
6,695 $578,000
Q1 2019

May 06, 2019

BUY
$34.3 - $97.98 $128,659 - $367,522
3,751 New
3,751 $288,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.34B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.